Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).
Clinical trial NCT02026362 · SUSPENDED
Trial details
- NCT number
- NCT02026362
- Sponsor
- HRYZ Biotech Co.
- Status
- SUSPENDED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-07-01
- Primary completion
- 2017-07-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.